BioCryst (Nasdaq: BCRX) granted inducement equity to 12 newly hired employees on April 1, 2026 under Nasdaq Listing Rule 5635(c)(4). The compensation committee awarded 33,950 stock options and 123,350 RSUs as of the grant date.
The options carry an exercise price of $9.38 (closing price on the grant date), a 10-year term, and both awards vest in four equal annual installments starting on the one-year anniversary, subject to continued service and plan terms.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
Key Figures
New hires granted options:12 employeesStock options granted:33,950 sharesRSUs granted:123,350 shares+3 more
6 metrics
New hires granted options12 employeesInducement stock option and RSU grants
Exercise price$9.38 per shareEqual to BCRX closing price on Apr 1, 2026 grant date
Vesting schedule4 equal annual installmentsBeginning one-year after Apr 1, 2026 grant date
Option term10 yearsTerm of inducement stock options
Market Reality Check
Price:$8.25Vol:Volume 7,070,490 is close...
normal vol
$8.25Last Close
VolumeVolume 7,070,490 is close to the 20-day average of 6,953,677 (relative volume 1.02).normal
TechnicalPrice at 9.03 is trading above the 200-day MA of 7.88.
Peers on Argus
BCRX is down 3.84% while several peers are flat or higher: HROW +2.91%, PAHC +4....
BCRX is down 3.84% while several peers are flat or higher: HROW +2.91%, PAHC +4.44%, BGM +6.06%, AMPH +2.51%, and AVDL 0.00%, suggesting stock-specific action.
Scheduling of Q4 2025 results release and related conference call.
Pattern Detected
Positive fundamental and clinical updates have recently coincided with positive price moves, while routine or administrative items have shown smaller mixed reactions.
Recent Company History
Over the last two months, BioCryst has combined solid fundamentals with ongoing news flow. Full year 2025 results on Feb 26 showed strong ORLADEYO revenue growth and record operating profit, and the stock rose 4.64%. Clinical and medical meeting updates on Feb 11 also saw a 4.43% gain. In contrast, administrative items such as earnings date notices and prior inducement grants in early February and early March produced modest, mixed reactions in the -1.38% to -2.80% range.
Market Pulse Summary
This announcement details routine inducement equity awards to 12 new employees, including 33,950 sto...
Analysis
This announcement details routine inducement equity awards to 12 new employees, including 33,950 stock options and 123,350 RSUs at an exercise price of $9.38. The grants vest annually over four years and have 10‑year terms, structured under Nasdaq Listing Rule 5635(c)(4). In context, BioCryst recently reported strong 2025 ORLADEYO revenues and record operating profits, so investors may track how ongoing hiring and equity usage support that growth trajectory.
"granted ... in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"stock options ... and restricted stock units (RSUs) covering an aggregate of 123,350 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock optionsfinancial
"granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise pricefinancial
"The options have an exercise price of $9.38 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
inducement equity incentive planfinancial
"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"
An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 123,350 shares, of BioCryst common stock. The options and RSUs were granted as of April 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $9.38 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
What did BioCryst (BCRX) grant to new hires on April 1, 2026?
BioCryst granted 33,950 stock options and 123,350 RSUs to 12 newly hired employees. According to the company, awards were made as inducements under Nasdaq Listing Rule 5635(c)(4) to facilitate new employee hires and align incentives with shareholders.
What is the exercise price and term of the stock options granted by BioCryst (BCRX)?
The stock options have an exercise price of $9.38 and a 10-year term. According to the company, $9.38 equals the closing price on the April 1, 2026 grant date and each option expires ten years after grant.
How do the BioCryst (BCRX) inducement awards vest for new employees?
The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant. According to the company, vesting is subject to each new employee’s continued service and the inducement plan terms.
Under what Nasdaq rule were BioCryst (BCRX) inducement awards granted?
Awards were granted under Nasdaq Listing Rule 5635(c)(4), which permits inducement grants for newly hired employees. According to the company, the compensation committee approved the grants in accordance with that Nasdaq rule.
How many employees received inducement awards from BioCryst (BCRX) and what aggregate amounts were granted?
Twelve newly hired employees received inducement awards totaling 33,950 options and 123,350 RSUs. According to the company, these aggregate amounts were granted as of April 1, 2026 to attract the new hires.
Are BioCryst (BCRX) inducement awards subject to additional agreements or plan terms?
Yes, the awards are subject to the company’s Inducement Equity Incentive Plan and individual award agreements. According to the company, each option or RSU is governed by the applicable stock option or restricted stock unit agreement.
